Andrea Cippitelli1, Gloria Brunori2, Jennifer Schoch2, Christopher J Armishaw2, Jinhua Wu2,3, Nurulain T Zaveri4, Marc A Giulianotti2,3, Gregory S Welmaker2,3, Lawrence Toll2,3. 1. Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port St. Lucie, FL, 34987, USA. acippitelli@tpims.org. 2. Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port St. Lucie, FL, 34987, USA. 3. Assuage Pharmaceuticals, Inc., 11350 SW Village Parkway, Port St. Lucie, FL, 34987, USA. 4. Astraea Therapeutics, LLC, 320 Logue Avenue, Mountain View, CA, 94043, USA.
Abstract
RATIONALE: Alcoholism is a serious public health problem throughout the world. Current pharmacotherapies for the treatment of this disorder are poorly effective. Preclinical and clinical findings point to nicotinic acetylcholine receptors (nAChRs) as a promising target for the development of novel and effective medications. Assuage Pharmaceuticals, in collaboration with Torrey Pines Institute for Molecular Studies, has discovered a new class of potent and selective α4β2 nAChR antagonists. OBJECTIVE: Here, it was hypothesized that α4β2 nAChR antagonism is a viable approach for treatment of alcohol use disorders. RESULTS: When tested in rats, one lead compound, AP-202, attenuated both operant alcohol and nicotine self-administration in a paradigm in which the two reinforcers were concurrently available. The conotoxin TP2212-59, a selective α3β4 nAChR antagonist, was only effective in reducing nicotine self-administration. AP-202 also reduced alcohol but not food responding when alcohol was presented as the only reinforcer, whereas the commercially available α4β2 nAChR antagonist dihydro-β-erythroidine failed to alter alcohol self-administration. AP-202 did not block relapse-like behavior induced by previously alcohol-associated stimuli or yohimbine stress. In a reinstatement paradigm, in which alcohol seeking was triggered by a nicotine challenge, a behavior successfully inhibited by the nonselective nAChR antagonist mecamylamine, AP-202 was not effective, while pretreatment with TP2212-59 abolished nicotine-induced reinstatement of alcohol seeking. CONCLUSIONS: These findings suggest differential roles for α4β2 and α3β4 nAChR on alcohol taking and seeking with selective blockade of α4β2 nAChR being more implicated in modulating alcohol taking while selective blockade of α3β4 nAChR is involved in nicotine-induced alcohol seeking.
RATIONALE: Alcoholism is a serious public health problem throughout the world. Current pharmacotherapies for the treatment of this disorder are poorly effective. Preclinical and clinical findings point to nicotinic acetylcholine receptors (nAChRs) as a promising target for the development of novel and effective medications. Assuage Pharmaceuticals, in collaboration with Torrey Pines Institute for Molecular Studies, has discovered a new class of potent and selective α4β2 nAChR antagonists. OBJECTIVE: Here, it was hypothesized that α4β2 nAChR antagonism is a viable approach for treatment of alcohol use disorders. RESULTS: When tested in rats, one lead compound, AP-202, attenuated both operant alcohol and nicotine self-administration in a paradigm in which the two reinforcers were concurrently available. The conotoxin TP2212-59, a selective α3β4 nAChR antagonist, was only effective in reducing nicotine self-administration. AP-202 also reduced alcohol but not food responding when alcohol was presented as the only reinforcer, whereas the commercially available α4β2 nAChR antagonist dihydro-β-erythroidine failed to alter alcohol self-administration. AP-202 did not block relapse-like behavior induced by previously alcohol-associated stimuli or yohimbine stress. In a reinstatement paradigm, in which alcohol seeking was triggered by a nicotine challenge, a behavior successfully inhibited by the nonselective nAChR antagonist mecamylamine, AP-202 was not effective, while pretreatment with TP2212-59 abolished nicotine-induced reinstatement of alcohol seeking. CONCLUSIONS: These findings suggest differential roles for α4β2 and α3β4 nAChR on alcohol taking and seeking with selective blockade of α4β2 nAChR being more implicated in modulating alcohol taking while selective blockade of α3β4 nAChR is involved in nicotine-induced alcohol seeking.
Authors: Susmita Chatterjee; Pia Steensland; Jeffrey A Simms; Joan Holgate; Jotham W Coe; Raymond S Hurst; Christopher L Shaffer; John Lowe; Hans Rollema; Selena E Bartlett Journal: Neuropsychopharmacology Date: 2010-11-03 Impact factor: 7.853
Authors: Omkar L Patkar; Arnauld Belmer; Josephine R Tarren; Joan Y Holgate; Selena E Bartlett Journal: Neurosci Lett Date: 2016-09-28 Impact factor: 3.046
Authors: Andrea Cippitelli; Ruslan Damadzic; Erick Singley; Annika Thorsell; Roberto Ciccocioppo; Robert L Eskay; Markus Heilig Journal: Pharmacol Biochem Behav Date: 2011-10-20 Impact factor: 3.533
Authors: Jinhua Wu; Andrea Cippitelli; Yaohong Zhang; Ginamarie Debevec; Jennifer Schoch; Akihiko Ozawa; Yongping Yu; Huan Liu; Wenteng Chen; Richard A Houghten; Gregory S Welmaker; Marc A Giulianotti; Lawrence Toll Journal: J Med Chem Date: 2017-12-13 Impact factor: 7.446
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams Journal: Neuropharmacology Date: 2006-12-08 Impact factor: 5.250
Authors: Jirawoot Srisontiyakul; Hanna E Kastman; Elena V Krstew; Piyarat Govitrapong; Andrew J Lawrence Journal: Neurochem Res Date: 2016-08-29 Impact factor: 3.996